Maleimidopropionic Acid CJC-1295 vs. Kisspeptin-10 Mechanics

In preclinical endocrine research, evaluating growth hormone secretagogues alongside gonadotropic regulatory peptides requires structural and functional clarity. Maleimidopropionic acid serves as the crucial Drug Affinity Complex (DAC) reactive group in modified CJC-1295, fundamentally altering its half-life compared to unmodified GRF (1-29) and neuroendocrine peptides like Kisspeptin-10. This technical reference examines chemical structures, receptor dynamics, and quality standards for analytical laboratory research.

GMP-compliant U.S. facilities
ISO 17025 third-party COAs
100% domestic — no imports
Fast tracked domestic shipping
Shop research peptides

Quick answer

In preclinical endocrine research, evaluating growth hormone secretagogues alongside gonadotropic regulatory peptides requires structural and functional clarity. Maleimidopropionic acid serves as the crucial Drug Affinity Complex (DAC) reactive group in modified CJC-1295, fundamentally altering its half-life compared to unmodified GRF (1-29) and neuroendocrine peptides like Kisspeptin-10. This technical reference examines chemical structures, receptor dynamics, and quality standards for analytical laboratory research.

Reviewed by PX1 Research scientific team

Key takeaways

  • Maleimidopropionic acid in [CJC-1295](/research-peptides/cjc-1295-no-dac) acts as a bioconjugating linker (Drug Affinity Complex or DAC) that covalently binds endogenous serum albumin in vivo, extending its active plasma half-life from minutes to over a week.
  • To understand the role of maleimidopropionic acid in peptide research, one must examine the molecular modifications applied to growth hormone-releasing hormone (GHRH) analogs.
  • The presence or absence of the maleimidopropionic acid moiety fundamentally alters experimental design when studying growth hormone dynamics.
  • Receptor selectivity forms the primary functional divide between maleimidopropionic acid [CJC-1295](/research-peptides/cjc-1295-no-dac) and [Kisspeptin](/research-peptides/kisspeptin-10)-10.

Direct Comparison: Maleimidopropionic Acid CJC-1295 vs. Kisspeptin-10

Maleimidopropionic acid in CJC-1295 acts as a bioconjugating linker (Drug Affinity Complex or DAC) that covalently binds endogenous serum albumin in vivo, extending its active plasma half-life from minutes to over a week. In contrast, Kisspeptin-10 is a short-acting 10-amino-acid peptide that targets the KISS1 receptor (GPR54) to stimulate gonadotropin-releasing hormone (GnRH) secretion without binding serum proteins.

While CJC-1295 DAC acts directly on pituitary growth hormone-releasing hormone receptors (GHRHr) to elevate continuous growth hormone (GH) and insulin-like growth factor 1 (IGF-1) release, Kisspeptin-10 operates within the hypothalamic-pituitary-gonadal (HPG) axis. Researchers comparing these compounds evaluate two entirely distinct endocrine pathways: sustained somatotropic axis activation versus acute gonadotropic pulse modulation.

Chemical Structure and the Role of Maleimidopropionic Acid

To understand the role of maleimidopropionic acid in peptide research, one must examine the molecular modifications applied to growth hormone-releasing hormone (GHRH) analogs. CJC-1295 is a synthetic 29-amino-acid peptide derived from the active N-terminal domain of native human GHRH (1-29). In its native state, unmodified GHRH (1-29) is rapidly degraded in biological fluids by dipeptidyl peptidase IV (DPP-IV) and renal clearance, yielding an effective elimination half-life of approximately 7 to 12 minutes.

To overcome rapid enzymatic cleavage, researchers incorporated specific amino acid substitutions (D-Ala2, Gln8, Ala15, and Leu27) to generate modified GRF (1-29), commonly referred to as CJC-1295 No DAC. To extend kinetic stability even further, chemists added a C-terminal maleimidopropionic acid linker. Maleimidopropionic acid contains an electrophilic maleimide group that selectively forms a covalent thioether bond with Cys34 of circulating albumin. This bioconjugation shields the peptide backbone from proteolytic degradation and prolongs plasma exposure significantly.

In contrast, Kisspeptin-10 (metastin 45-54) is a minimal functional cleavage product of the KISS1 precursor protein, consisting of the sequence Tyr-Asn-Trp-Asn-Ser-Phe-Gly-Leu-Arg-Phe-NH2. It possesses no maleimidopropionic acid modification or bioconjugation motif. Consequently, Kisspeptin-10 exhibits rapid clearance in rodent and non-human primate research models, requiring specific experimental dosing schedules or constant infusion protocols to measure persistent KISS1R downstream activation.

Pharmacokinetics and Pharmacodynamics: DAC vs. Non-DAC CJC-1295

The presence or absence of the maleimidopropionic acid moiety fundamentally alters experimental design when studying growth hormone dynamics. Formulations containing maleimidopropionic acid (CJC-1295 with DAC) display an extended half-life estimated at 6 to 8 days in rodent models, maintaining baseline baseline GH and IGF-1 elevation through continuous GHRH receptor stimulation.

Conversely, formulations lacking maleimidopropionic acid (CJC-1295 No DAC) demonstrate a plasma half-life of roughly 30 minutes. Non-DAC preparations elicit discrete, transient pulses of growth hormone release that closely mimic physiological GHRH secretory spikes. In comparative studies within our research library, investigators choose between maleimidopropionic acid-modified CJC-1295 and non-DAC variants depending on whether their target outcome relies on sustained basal IGF-1 upregulation or natural episodic GH pulsatility.

When comparing both CJC-1295 variants to Kisspeptin-10, clear kinetic distinctions emerge. Kisspeptin-10 exhibits a rapid circulating half-life of 2 to 22 minutes depending on the test organism. Rather than influencing the somatotropic line, Kisspeptin-10 acts rapidly at the central nervous system level to induce luteinizing hormone (LH) and follicle-stimulating hormone (FSH) secretion via hypothalamic GnRH neurons.

Endocrine Pathways: Somatotropic Axis vs. HPG Axis

Receptor selectivity forms the primary functional divide between maleimidopropionic acid CJC-1295 and Kisspeptin-10. CJC-1295 binds specifically to the G-protein coupled GHRH receptor (GHRHr) located on anterior pituitary somatotropes. Receptor occupancy activates intracellular adenylate cyclase, raising cyclic AMP (cAMP) and intracellular calcium levels, which prompts transcription and secretion of endogenous growth hormone. Downstream in vitro and animal models show that elevated circulating GH triggers hepatic synthesis of IGF-1, promoting cellular proliferation, protein synthesis, and lipid oxidation.

Kisspeptin-10 targets the KISS1 receptor (KISS1R, formerly GPR54), a Gq/11-coupled receptor expressed densely on GnRH-releasing neurons in the hypothalamus. Upon binding, Kisspeptin-10 stimulates phospholipase C (PLC), initiating intracellular inositol trisphosphate (IP3) and diacylglycerol (DAG) cascades. This triggers the release of GnRH into the hypophyseal portal circulation, stimulating anterior pituitary gonadotropes to release LH and FSH into system circulation.

Because maleimidopropionic acid CJC-1295 targets metabolic and somatotropic pathways while Kisspeptin-10 regulates reproductive neuroendocrine pathways, these research compounds are frequently evaluated in distinct or complementary physiological models. Researchers investigating lean tissue accrual, cartilage repair, or cellular regeneration typically focus on growth hormone secretagogues, whereas studies exploring central reproductive signal transduction utilize Kisspeptin-10.

Analytical Criteria and Quality Control Standards

Preclinical outcomes depend entirely on compound purity, correct molecular structure, and absolute chemical identification. When sourcing research peptides, laboratory personnel must ensure that maleimidopropionic acid-modified CJC-1295 and Kisspeptin-10 meet rigorous analytical benchmarks prior to reconstitution.

At PX1 Research, all production lots undergo mandatory testing in an independent, ISO 17025-accredited laboratory. Verification procedures include:

- Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC): Establishes chemical purity to a minimum threshold of 99%, eliminating truncated peptides, side products, and free maleimidopropionic acid fragments.

- Electrospray Ionization Mass Spectrometry (ESI-MS): Confirms exact molecular mass (CJC-1295 DAC exact mass: 3647.28 Da; Kisspeptin-10 exact mass: 1301.47 Da) to guarantee structural identity.

- Endotoxin Quantitation (LAL Assay): Ensures bacterial endotoxin levels remain below strictly defined threshold limits (<0.01 EU/mg) to avoid confounding cellular responses or unwanted inflammatory responses in cell culture and animal models.

- Lot-Specific Certificate of Analysis (COA): Every vial shipped from our CA and AZ facilities carries a verifiable batch-specific COA containing full HPLC chromatograms and mass spectra.

Researchers seeking large-scale or long-term analytical projects can request customized documentation through our wholesale laboratory accounts portal.

Handling, Reconstitution, and Storage Protocols for Laboratory Use

Maintaining structural integrity during reconstitution and storage is critical for both maleimidopropionic acid CJC-1295 and Kisspeptin-10. Lyophilized peptide cakes should be inspected upon arrival to confirm vacuum seal integrity.

Lyophilized vials should be stored at -20°C for short-term projects (less than 3 months) or -80°C for long-term preservation. Exposure to ambient temperatures, moisture, and light should be strictly minimized to prevent peptide oxidation or deamidation.

For reconstitution, sterile bacteriostatic water (0.9% benzyl alcohol) or laboratory-grade sterile water for injection should be introduced along the internal glass wall of the vial. Direct high-velocity impact on the lyophilized cake should be avoided to prevent mechanical agitation and structural shearing. Gentle rotation or swirling of the vial is recommended; never vortex peptide solutions.

Once reconstituted, maleimidopropionic acid CJC-1295 and Kisspeptin-10 solutions remain stable at 2°C to 8°C for up to 30 days. For extended assay timelines, reconstituted aliquots should be frozen at -80°C to eliminate repeated freeze-thaw cycles, which degrade secondary molecular structures.

Comparative Analysis within the Growth Hormone Secretagogue Class

In experimental models evaluating growth hormone elevation, CJC-1295 variants are frequently compared with other synthetic peptides targeting the somatotropic pathway. Understanding where maleimidopropionic acid CJC-1295 fits relative to its peers aids in selecting appropriate reagents.

When evaluated alongside sermorelin, which consists of the native 1-29 sequence of GHRH without structural substitutions or bioconjugation linkers, CJC-1295 displays significantly greater enzymatic stability against DPP-IV. While sermorelin requires frequent administration due to its rapid elimination, CJC-1295 No DAC provides an extended pulse window, and maleimidopropionic acid CJC-1295 maintains continuous multi-day receptor engagement.

Compared to tesamorelin—a GHRH analog modified with a trans-3-hexenoic acid group tailored for metabolic research—maleimidopropionic acid CJC-1295 exhibits a substantially longer terminal half-life due to its albumin-binding capacity. When paired in dual-pathway protocols with ghrelin mimetics such as ipamorelin or ghrp-6, non-DAC CJC-1295 elicits synergistic growth hormone output without causing hypercortisolemia or excessive prolactin release.

Preclinical Applications and Experimental Protocols

In preclinical settings, maleimidopropionic acid CJC-1295 is primarily utilized in studies examining skeletal muscle protein synthesis, nitrogen retention, metabolic rate modulation, and connective tissue repair. Because the maleimidopropionic acid group prolongs baseline IGF-1 levels, it is favored in long-term rodent models evaluating age-related somatopause, body composition changes, and wound healing dynamics.

Conversely, Kisspeptin-10 is deployed in reproductive endocrinology studies investigating pubertal onset, LH pulse frequency, fertility restoration, and hypothalamic feedback mechanisms. Experimental assays frequently utilize Kisspeptin-10 to evaluate how central neural circuits process metabolic signals (such as leptin or insulin) to regulate reproductive capability.

Both compounds serve distinct roles in preclinical methodologies. Researchers seeking to study both systems simultaneously must account for the vastly different clearance kinetics between albumin-bound maleimidopropionic acid CJC-1295 and rapidly cleared Kisspeptin-10.

Sourcing USA-Manufactured Research Peptides from PX1 Research

Reliability in scientific experimentation demands reagents produced under strict quality standards. PX1 Research manufactures all research peptides in compliant USA facilities, adhering to rigorous ISO 17025 and GMP-aligned protocols.

Orders placed before 12:00 PM PST ship same-day from our dual distribution centers in California and Arizona, minimizing transit times and cold-chain exposure. Every batch of CJC-1295 DAC, CJC-1295 No DAC, and Kisspeptin-10 is accompanied by verified, lot-traceable analytical data available directly on our website or through our research account services.

Frequently Asked Questions

What is the specific function of maleimidopropionic acid in CJC-1295 formulations?

Maleimidopropionic acid serves as the bioconjugating Drug Affinity Complex (DAC) linker attached to the C-terminus of CJC-1295. It contains a reactive maleimide group that binds selectively and covalently to the Cys34 residue of circulating serum albumin in vivo, extending the peptide's elimination half-life from minutes to up to 8 days.

How does CJC-1295 with maleimidopropionic acid differ from CJC-1295 No DAC?

CJC-1295 with maleimidopropionic acid (CJC-1295 DAC) binds serum albumin to maintain a prolonged half-life of 6 to 8 days, leading to continuous growth hormone elevation. CJC-1295 No DAC (Modified GRF 1-29) lacks the maleimidopropionic acid linker, resulting in a short half-life of roughly 30 minutes that induces acute, pulsatile growth hormone release.

How does the mechanism of CJC-1295 compare to Kisspeptin-10 in laboratory research?

CJC-1295 acts as an agonist at the pituitary growth hormone-releasing hormone receptor (GHRHr) to stimulate GH and IGF-1 secretion. Kisspeptin-10 targets the hypothalamic KISS1 receptor (KISS1R) to trigger gonadotropin-releasing hormone (GnRH) release, elevating LH and FSH within the reproductive endocrine axis.

What are the primary receptor targets for Kisspeptin-10 versus CJC-1295?

Kisspeptin-10 targets the central Gq/11-coupled KISS1 receptor (GPR54) on GnRH neurons in the hypothalamus. CJC-1295 targets the G-protein-coupled GHRH receptor on anterior pituitary somatotropes.

What purity standards are required for analytical research with these peptides?

Analytical research requires a minimum of 99% peptide purity verified by Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC) and exact mass confirmation by Electrospray Ionization Mass Spectrometry (ESI-MS). Endotoxin levels must measure below 0.01 EU/mg to prevent confounding cell culture or animal assays.

How should maleimidopropionic acid CJC-1295 and Kisspeptin-10 be reconstituted?

Both peptides should be reconstituted using sterile bacteriostatic water or sterile water for injection. The diluent should be gently trickled down the inside wall of the glass vial to prevent mechanical agitation, followed by gentle swirling until complete dissolution is achieved.

What is the half-life difference between CJC-1295 with DAC and Kisspeptin-10?

CJC-1295 with DAC (containing maleimidopropionic acid) exhibits an extended half-life of 6 to 8 days due to albumin binding. Kisspeptin-10 exhibits a short circulating half-life of approximately 2 to 22 minutes in biological models.

How does PX1 Research verify batch purity and endotoxin levels?

PX1 Research conducts third-party laboratory testing for every production lot using RP-HPLC for purity, ESI-MS for structural mass identity, and chromogenic LAL assays for endotoxin quantification. Every lot includes a downloadable Certificate of Analysis (COA).

Can CJC-1295 and Kisspeptin-10 be evaluated in the same physiological research model?

Yes, in preclinical research evaluating cross-talk between the somatotropic and reproductive axes, both peptides may be studied. However, researchers must account for their different signaling pathways (GHRHr vs. KISS1R) and kinetic profiles.

What are the recommended storage conditions for lyophilized research peptides?

Lyophilized vials should be stored protected from light at -20°C for short-term preservation or -80°C for long-term storage. Reconstituted peptide solutions should be kept refrigerated at 2°C to 8°C and used within 30 days.

Related pages

All products are sold strictly for laboratory and research use only. Not for human or veterinary use, diagnosis, treatment or consumption. Statements have not been evaluated by the FDA.